Working… Menu

Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen) (CaboPen)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03943602
Recruitment Status : Recruiting
First Posted : May 9, 2019
Last Update Posted : February 25, 2021
Information provided by (Responsible Party):
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Brief Summary:
Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen)

Condition or disease Intervention/treatment Phase
Penile Squamous Cell Carcinoma Drug: Cabozantinib Phase 2

Detailed Description:
an open-label, single-center, phase 2, single-arm trial

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 37 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)
Actual Study Start Date : August 1, 2019
Estimated Primary Completion Date : June 1, 2022
Estimated Study Completion Date : September 1, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Cabozantinib
Cabozantinib will be administered orally at a dose of 60 mg/day continuously until 28 days prior to planned surgery or at time of the evidence of disease progression or onset of unacceptable toxicity.
Drug: Cabozantinib
Cabozantinib 60 mg/day orally

Primary Outcome Measures :
  1. response -rate by RECIST v1.1 criteria [ Time Frame: 40 months ]
    Assessment of response-rate by RECIST v1.1. Complete response + partial response

Secondary Outcome Measures :
  1. Incidence of treatment-Emergent Adverse Event(safety and tolerability) [ Time Frame: 40 months ]
    Assessment of the safety and tolerability: incidence, nature and severity of treatment-related adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

  2. Pathologic complete response (pCR) [ Time Frame: 40 months ]
    Histological report of radical surgery

  3. Progression-free survival (PFS). [ Time Frame: 40 months ]
    Recist 1.1 criteria

  4. Overall Survival (OS). [ Time Frame: 40 months ]
    time will be calculated as the interval from treatment start date to the date of death for any cause, with censoring at the date of last contact for patients alive.

  5. Variations of the Quality of Life [ Time Frame: 40 months ]

    Variations of the Quality of Life score as assessed with the Edmonton Symptom Assessment Scale (ESAS), validated in Italian language. In this quality of life there are specify 9 main symptons: the score range is from 0 to 10 for each one.

    For each symptom the "0 score" corrisponds to "no symptom present" (better outcome) and the "10 score" corrisponds to "maximum symptom assessable" (worse outcome). The listed symptoms are: 1) Pain 2) Fatigue 3) Nausea 4) Depression 5) Anxiety 6) Somnolence 7) Loss of appetite 8) General Malaise 9) Dispnea. The total score is ranging from 0 to 90

  6. FDG-PET/CT response rate according to EORTC criteria [ Time Frame: 40 months ]
    1. to determine the rate of concordance with CT scan RECIST 1.1 response criteria and PET/CT EORTC Criteria

      • Complete response: complete disappearance of all target lesions with the exception of nodal disease (RECIST 1.1) and Complete resolution of FDG uptake in all lesions (EORTC)
      • Partial response (PR): greater than or equal to 30% decrease under baseline of the sum of target lesions (RECIST 1.1) and ≥ 25% reduction in the sum of SUVmax
      • Stable disease (SD): Not qualify for CR, PR or PD
      • Objective Progression (PD): 20% increase in the sum of diameters of target lesions or appearance of new unequivocal malignant lesions (RECIST 1.1) and ≥ 25% Increase in the sum of SUVmax or appearance of new lesions.
    2. To evaluate the relationship existing between tumor response measured by FDG-PET/CT EORTC Criteria (mainly early PET response as evaluated at first restaging) and pCR-rate (pT0 after surgery) and progression-free survival (months).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18-75
  2. Written informed consent
  3. ECOG (Eastern Cooperative Oncology Group) performance status 0-1
  4. Cytologically or histologically proven diagnosis of PSCC.
  5. Histologically (Tru-cut biopsy) proven diagnosis of loco-regional nodal disease will be required in all cases except for those with clinical contraindications.
  6. Uni- or bidimensionally measurable disease as defined by RECIST v1.1 criteria.
  7. Clinical stage N2-3 and/or M1 (TNM 2002).
  8. Locoregional relapse after prior major surgery/ies (either single or multiple).
  9. No prior systemic therapy except for the administration of VBM (Vinblastine, Bleomycin, Methotrexate) chemotherapy for superficial disease if administered at least 6 months prior to study enrolment.
  10. Adequate organ and marrow function .
  11. Patients must be accessible for treatment and follow up as well as they must be willing and capable to comply with the requirements of the study. Patients registered on this trial must be treated and followed at the study sponsor site.

Exclusion Criteria:

  1. History of any one or more of the following cardiovascular conditions within the past 6 months:

    • Cardiac angioplasty or stenting.
    • Myocardial infarction.
    • Unstable angina.
    • Coronary artery by-pass graft surgery.
    • Symptomatic peripheral vascular disease.
    • Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA).
    • Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted during the study but should be used with caution - please refer to the study drug IB).
    • Screening ECG with a QTc>450 msec, congenital long QT syndrome, history of sustained ventricular tachycardia, history of ventricular fibrillation or torsade de pointes, bradycardia defined as heart rate < 50 bpm (patients with a pacemaker and heart rate > 50 bpm are eligible).
    • Uncontrolled hypertension.
  2. History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months ior to first dose of study drug.
  3. History of HIV infection or active chronic hepatitis B or C.
  4. Active clinically serious infections (> grade 2 NCI-CTC version 5.0).
  5. Patients with seizure disorder requiring medication (such as steroids or anti-epileptics).
  6. Patients undergoing renal dialysis
  7. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT treated basal cell carcinoma or any cancer curatively treated > 5 years prior to study entry.
  8. History of clinically-significant gastrointestinal bleeding, inflammatory bowel disease, and other GI disorders associated with high risk of perforation or fistula formation or any other condition.
  9. Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
  10. Major surgery within 12 weeks before the first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment. Minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.
  11. History of allogenic organ solid transplantation.
  12. Fertile males not willing to use a highly effective method of contraception or whose female partner is not using a highly effective contraception protection.
  13. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
  14. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.
  15. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug.
  16. Hemoptysis >=2.5 ml red blood within 3 months before treatment, signs indicative of pulmonary hemorrhage, cavitating pulmonary lesion, tumor invading major blood vessels and/or GI tract, endotracheal or endobronchial tumors History of clinically-significant gastrointestinal bleeding, inflammatory bowel disease, or any other condition among those listed in the full protocol.
  17. Patients unable to swallow oral medications.
  18. Concomitant anticoagulation with oral anticoagulants or platelet inhibitors.
  19. History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03943602

Layout table for location contacts
Contact: Daniele Raggi, MD +390223902402
Contact: Michela Rizzuti, Dr.ssa +390223903067

Layout table for location information
Fondazione IRCCS Istituto Nazionale dei Tumori Recruiting
Milano, Italy, 20133
Contact: Daniela Raggi, MD    +390223902402   
Sponsors and Collaborators
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Layout table for investigator information
Study Chair: Daniele Raggi, MD Fondazione IRCCS Istituto Nazionale Tumori

Layout table for additonal information
Responsible Party: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Identifier: NCT03943602    
Other Study ID Numbers: CaboPen
First Posted: May 9, 2019    Key Record Dates
Last Update Posted: February 25, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell